Back to today’s briefing

Story perspectives

Novo Nordisk's Oral Semaglutide Reduces Heart Risks in Diabetes

4/10/2025

43 4

Summary

Story summary

Novo Nordisk's groundbreaking SOUL trial shows that oral semaglutide significantly lowers major heart risks for type 2 diabetes patients with heart or kidney issues, cutting the chances of heart attack, stroke, and heart-related death by 14%. With a solid safety record, this promising treatment could transform diabetes care, with regulatory updates expected in 2025.

1 of 1

Story summary

Novo Nordisk's groundbreaking SOUL trial shows that oral semaglutide significantly lowers major heart risks for type 2 diabetes patients with heart or kidney issues, cutting the chances of heart attack, stroke, and heart-related death by 14%. With a solid safety record, this promising treatment could transform diabetes care, with regulatory updates expected in 2025.